FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3215348306> ?p ?o ?g. }

• W3215348306 endingPage "2497" @default.
• W3215348306 startingPage "2497" @default.
• W3215348306 abstract "Abstract Background Diffuse large B-cell lymphoma (DLBCL) is the most frequent subtype of HIV-associated lymphoma. Since the introduction of combined antiretroviral therapy (cART), the prognosis of HIV-related DLBCL has substantially improved, resembling that of the general population. However, non-Hodgkin lymphoma still remains the first cause of AIDS-related deaths. The International Prognostic Index (IPI) is the most widely used score for DLBCL and it has been validated in the rituximab era (R-IPI). However, it has limited accuracy to identify a very high-risk prognostic subset. Although IPI has been demonstrated to be useful for predicting prognosis in HIV-related DLBCL, new scores subsequently developed, such as National Cancer Comprehensive Network IPI (NCCN-IPI), GELTAMO-IPI and a new score, which includes data from peripheral blood count, have not been applied in the HIV setting. The aim of this study was to assess the prognostic significance of the new variables -beta2-microglobulin (β2M), lymphocyte/monocyte (L/M) ratio and red blood cell width (RDW)- and to validate the new scores in a series of homogeneously treated HIV-related DLBCL patients. Methods Retrospective multicentric study of patients with HIV infection diagnosed with DLBCL in 16 hospitals from GELTAMO group in Spain, from 1998 to 2020. All patients were treated with R-CHOP and cART +/- radiotherapy. The main clinical and biological variables were collected. Peripheral absolute neutrophil, lymphocyte and monocyte counts were studied, including L/M ratio and CD4 + lymphocyte count. Moreover, HIV load, serum lactate dehydrogenase (LDH), β2M and RDW were evaluated. Univariable and multivariable analysis were performed using the binary logistic regression model for complete response (CR) rate and Cox proportional-hazards regression model for overall survival (OS) and progression-free survival (PFS). Survival curves were plotted by the Kaplan-Meier method and compared by the log-rank test. The discrimination power of IPI, aaIPI (age-adjusted IPI), R-IPI, NCCN-IPI, GELTAMO-IPI and the new score including L/M ratio (L Bento et al., Br J Haematol. 2020) was assessed by the C-index. Results One hundred and five patients were retrospectively analysed with a median follow up of 7.08 (0.36-25.21) years. The characteristics of the patients are summarized in Table 1. In the univariable analysis, performance status ≥2, extranodal sites ≥2, lymphocytopenia and low L/M ratio were associated with shorter OS and shorter PFS probabilities. Neutropenia was also associated with lower OS and advanced Ann Arbor stage was associated with lower PFS. On the other hand, monocytosis, low CD4 + lymphocyte count, positive HIV load and high values of serum LDH, RDW and β2M had no prognostic impact. By multivariable analysis, only L/M ratio &lt;3 emerged as an unfavourable prognostic factor for OS and PFS, with harzard ratios (HR) (95%CI) of 2.515 (1.256;5.039) and 2.563 (1.314;5), respectively (Figure 1). With the aim of validating the prognostic power of each score system, the patients were divided in two groups: patients corresponding with low or intermediate-low risk versus those with intermediate-high or high risk. R-IPI, NCCN-IPI and the new score including L/M ratio showed significant differences in two groups for CR rate, OS and PFS. IPI also significantly discriminated the groups for PFS. NCCN-IPI was the strongest score to discriminate OS with a C-index of 0.638, and the new score including L/M ratio was the best one for CR rate and PFS discrimination, with a C-index of 0.669 and 0.666 respectively. Conclusions Lymphocyte/monocyte ratio is a strong prognostic factor, which can be used in patients with DLBCL and HIV infection. NCCN-IPI and the new score including L/M ratio provided the best discriminative capacity to predict prognosis in patients with HIV-related DLBCL treated with R-CHOP and cART. Supported in part by Gilead Sciences S.L., Spain (GLD19/00121); 2017 SGR288 (GRE) from CERCA Programme/Generalitat de Catalunya, and by funds from Josep Carreras International Foundation and la Caixa Foundation. Figure 1 Figure 1. Disclosures Lopez-Guillermo: Roche, Gilead/Kite, Celgene, Novartis, Janssen, AbbVie, Spectrum: Consultancy, Honoraria, Research Funding. Salar: Janssen: Consultancy, Speakers Bureau; Roche: Consultancy, Speakers Bureau; Celgene: Consultancy, Speakers Bureau; Gilead: Research Funding. de la Cruz Vicente: Takeda: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Roche: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Kyowa Kirin: Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Eusapharma: Membership on an entity's Board of Directors or advisory committees; Beigene: Membership on an entity's Board of Directors or advisory committees; Abbvie: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Ferrer Lores: Janssen: Membership on an entity's Board of Directors or advisory committees. Abrisqueta: Janssen: Consultancy, Honoraria; Abbvie: Consultancy, Honoraria; Roche: Consultancy, Honoraria; BMS: Consultancy, Honoraria; AstraZeneca: Consultancy, Honoraria. Sancho: Roche, Janssen, Celgene-BMS, Gilead, Novartis, Takeda: Honoraria, Speakers Bureau; Roche, Janssen, Celgene-BMS, Gilead, Novartis, Incyte, Beigene: Speakers Bureau. Ribera: SHIRE: Consultancy, Speakers Bureau; ARIAD: Consultancy, Research Funding, Speakers Bureau; TAKEDA: Consultancy, Research Funding, Speakers Bureau; NOVARTIS: Consultancy, Speakers Bureau; AMGEN: Consultancy, Research Funding, Speakers Bureau; Pfizer: Consultancy, Research Funding, Speakers Bureau. Navarro: NOVARTIS, Roche: Honoraria; EUSA Pharma: Consultancy; GILEAD, EUSA Pharma: Research Funding." @default.
• W3215348306 created "2021-12-06" @default.
• W3215348306 creator A5000723805 @default.
• W3215348306 creator A5002877018 @default.
• W3215348306 creator A5006074198 @default.
• W3215348306 creator A5006538688 @default.
• W3215348306 creator A5007117385 @default.
• W3215348306 creator A5010206363 @default.
• W3215348306 creator A5010733763 @default.
• W3215348306 creator A5012630795 @default.
• W3215348306 creator A5014791873 @default.
• W3215348306 creator A5020455030 @default.
• W3215348306 creator A5020921101 @default.
• W3215348306 creator A5023740017 @default.
• W3215348306 creator A5027815550 @default.
• W3215348306 creator A5034861019 @default.
• W3215348306 creator A5036150684 @default.
• W3215348306 creator A5041947693 @default.
• W3215348306 creator A5052267535 @default.
• W3215348306 creator A5053964161 @default.
• W3215348306 creator A5055373910 @default.
• W3215348306 creator A5055406905 @default.
• W3215348306 creator A5069388075 @default.
• W3215348306 creator A5074962085 @default.
• W3215348306 creator A5083191976 @default.
• W3215348306 date "2021-11-05" @default.
• W3215348306 modified "2023-10-09" @default.
• W3215348306 title "Validation of New International Prognostic Scores, Including Baseline Peripheral Blood Variables, in Patients with Diffuse Large B-Cell Lymphoma and HIV Infection Treated with R-CHOP and Combined Antiretroviral Therapy. Retrospective Study from Spanish Lymphoma Group Geltamo" @default.
• W3215348306 doi "https://doi.org/10.1182/blood-2021-148361" @default.
• W3215348306 hasPublicationYear "2021" @default.
• W3215348306 type Work @default.
• W3215348306 sameAs 3215348306 @default.
• W3215348306 citedByCount "0" @default.
• W3215348306 crossrefType "journal-article" @default.
• W3215348306 hasAuthorship W3215348306A5000723805 @default.
• W3215348306 hasAuthorship W3215348306A5002877018 @default.
• W3215348306 hasAuthorship W3215348306A5006074198 @default.
• W3215348306 hasAuthorship W3215348306A5006538688 @default.
• W3215348306 hasAuthorship W3215348306A5007117385 @default.
• W3215348306 hasAuthorship W3215348306A5010206363 @default.
• W3215348306 hasAuthorship W3215348306A5010733763 @default.
• W3215348306 hasAuthorship W3215348306A5012630795 @default.
• W3215348306 hasAuthorship W3215348306A5014791873 @default.
• W3215348306 hasAuthorship W3215348306A5020455030 @default.
• W3215348306 hasAuthorship W3215348306A5020921101 @default.
• W3215348306 hasAuthorship W3215348306A5023740017 @default.
• W3215348306 hasAuthorship W3215348306A5027815550 @default.
• W3215348306 hasAuthorship W3215348306A5034861019 @default.
• W3215348306 hasAuthorship W3215348306A5036150684 @default.
• W3215348306 hasAuthorship W3215348306A5041947693 @default.
• W3215348306 hasAuthorship W3215348306A5052267535 @default.
• W3215348306 hasAuthorship W3215348306A5053964161 @default.
• W3215348306 hasAuthorship W3215348306A5055373910 @default.
• W3215348306 hasAuthorship W3215348306A5055406905 @default.
• W3215348306 hasAuthorship W3215348306A5069388075 @default.
• W3215348306 hasAuthorship W3215348306A5074962085 @default.
• W3215348306 hasAuthorship W3215348306A5083191976 @default.
• W3215348306 hasBestOaLocation W32153483061 @default.
• W3215348306 hasConcept C126322002 @default.
• W3215348306 hasConcept C143998085 @default.
• W3215348306 hasConcept C167135981 @default.
• W3215348306 hasConcept C203014093 @default.
• W3215348306 hasConcept C2778476033 @default.
• W3215348306 hasConcept C2778559949 @default.
• W3215348306 hasConcept C2779338263 @default.
• W3215348306 hasConcept C2779725641 @default.
• W3215348306 hasConcept C2780653079 @default.
• W3215348306 hasConcept C2908647359 @default.
• W3215348306 hasConcept C71924100 @default.
• W3215348306 hasConcept C99454951 @default.
• W3215348306 hasConceptScore W3215348306C126322002 @default.
• W3215348306 hasConceptScore W3215348306C143998085 @default.
• W3215348306 hasConceptScore W3215348306C167135981 @default.
• W3215348306 hasConceptScore W3215348306C203014093 @default.
• W3215348306 hasConceptScore W3215348306C2778476033 @default.
• W3215348306 hasConceptScore W3215348306C2778559949 @default.
• W3215348306 hasConceptScore W3215348306C2779338263 @default.
• W3215348306 hasConceptScore W3215348306C2779725641 @default.
• W3215348306 hasConceptScore W3215348306C2780653079 @default.
• W3215348306 hasConceptScore W3215348306C2908647359 @default.
• W3215348306 hasConceptScore W3215348306C71924100 @default.
• W3215348306 hasConceptScore W3215348306C99454951 @default.
• W3215348306 hasIssue "Supplement 1" @default.
• W3215348306 hasLocation W32153483061 @default.
• W3215348306 hasOpenAccess W3215348306 @default.
• W3215348306 hasPrimaryLocation W32153483061 @default.
• W3215348306 hasRelatedWork W1983309704 @default.
• W3215348306 hasRelatedWork W2046188170 @default.
• W3215348306 hasRelatedWork W2292265136 @default.
• W3215348306 hasRelatedWork W2338940907 @default.
• W3215348306 hasRelatedWork W2390430401 @default.
• W3215348306 hasRelatedWork W2899250601 @default.
• W3215348306 hasRelatedWork W2979564713 @default.
• W3215348306 hasRelatedWork W2993375378 @default.
• W3215348306 hasRelatedWork W3031860663 @default.
• W3215348306 hasRelatedWork W79716904 @default.
• W3215348306 hasVolume "138" @default.
• W3215348306 isParatext "false" @default.

• next